Could changing the order of two cancer drugs boost their power?

NCT ID NCT07285850

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving the drug bevacizumab alone first, then adding atezolizumab later, works better than giving both drugs together from the start. It involves 20 adults with advanced liver cancer who also have fatty liver disease. The goal is to see if the sequential approach improves tumor shrinkage and survival while keeping side effects manageable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
bevacizumab and atezolizumab (drugs given by IV)
What this could lead to
If successful, this could point toward a more effective way to treat advanced liver cancer in people with fatty liver disease, potentially improving response rates and survival.
What could go wrong
This is a small early-phase trial with only 20 participants, so results may not apply widely. The drugs can cause serious side effects like bleeding or immune reactions, and the sequential approach may not prove better than the standard combination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Eastern Hepatobiliary Surgery Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 201805, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.